Docetaxel nanoparticle - Cristal Therapeutics

Drug Profile

Docetaxel nanoparticle - Cristal Therapeutics

Alternative Names: CriPec® docetaxel

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cristal Therapeutics
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 06 Dec 2017 Chemical structure information added
  • 01 Nov 2017 Cristal Therapeutics initiated a phase Ib trial for Solid tumours in Belgium and Netherlands
  • 05 Jul 2017 Erasmus Medical Center and Cristal Therapeutics initiate the phase I CRITAX trial for Solid tumours in Netherlands (NTR6474)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top